Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
